Patrizi, C; Llado, M; Benati, D; Iodice, C; Marrocco, E; Guarascio, R; Surace, EM; ... Recchia, A; + view all Patrizi, C; Llado, M; Benati, D; Iodice, C; Marrocco, E; Guarascio, R; Surace, EM; Cheetham, ME; Auricchio, A; Recchia, A; - view fewer (2021) Allele-specific editing ameliorates dominant retinitis pigmentosa in a transgenic mouse model. American Journal of Human Genetics , 108 (2) pp. 295-308. 10.1016/j.ajhg.2021.01.006.

Preview

Text Cheetham_1-s2.0-S0002929721000069-main.pdf - Published Version Download (2MB) | Preview

Abstract

Retinitis pigmentosa (RP) is a group of progressive retinal degenerations of mostly monogenic inheritance, which cause blindness in about 1:3,500 individuals worldwide. Heterozygous variants in the rhodopsin (RHO) gene are the most common cause of autosomal dominant RP (adRP). Among these, missense variants at C-terminal proline 347, such as p.Pro347Ser, cause severe adRP recurrently in European affected individuals. Here, for the first time, we use CRISPR/Cas9 to selectively target the p.Pro347Ser variant while preserving the wild-type RHO allele in vitro and in a mouse model of adRP. Detailed in vitro, genomic, and biochemical characterization of the rhodopsin C-terminal editing demonstrates a safe downregulation of p.Pro347Ser expression leading to partial recovery of photoreceptor function in a transgenic mouse model treated with adeno-associated viral vectors. This study supports the safety and efficacy of CRISPR/Cas9-mediated allele-specific editing and paves the way for a permanent and precise correction of heterozygous variants in dominantly inherited retinal diseases.

Download activity - last month

Export as CSVXMLJSON

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as XMLCSVJSON

Archive Staff Only

View Item